Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases

S

State Scientific Centre of Coloproctology, Russian Federation

Status

Enrolling

Conditions

Colonic Disease
Gastrointestinal Diseases
Intestinal Diseases
Neoplasms by Site
Digestive System Diseases
Neoplasm Metastasis
Digestive System Neoplasms
Gastrointestinal Neoplasms
Neoplasms, Second Primary
Intestinal Neoplasms
Neoplasms
Rectal Diseases
Colorectal Neoplasms

Treatments

Drug: chemotherapy
Procedure: surgery of the primary tumour

Study type

Observational

Funder types

Other

Identifiers

NCT05322486
22A/20

Details and patient eligibility

About

Currently, the question remains whether palliative primary tumor resection could improve overall survival of minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases. The aim of this study is to determine if there is an improvement in overall survival of palliative primary tumor resection followed by chemotherapy in minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases compared to those of upfront chemotherapy/radiotherapy alone.

Full description

The present study is a single-center retrospective observational cohort study with a propensity score matching. Between 2016 and 2022 from our institutional database minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases will be selected. Patients will be divided into two groups: Surgical resection of the primary tumour before to systemic therapy Systemic therapy without previous resection of the primary tumour. Propensity score matching (PSM) will be performed, to minimize the selection bias by adjusting variables that may affect the survival of patients. Categorical variables will be compared using the chi-square test or Fisher's exact test. Continuous variables will be compared using the Student's t-test or Mann-Whitney U test. Survival rate will be determined by using Kaplan-Meier analysis with a log-rank test. Univariate and multivariate analyses for survival will be conducted using Cox proportional hazard models. Statistical results will be considered significant at p values less than 0.05.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histologically confirmed colorectal adenocarcinoma
  2. Resectable minimally symptomatic primary tumor with unresectable synchronous metastasis
  3. Age ≥ 18 years
  4. Informed consent

Exclusion criteria

  1. Synchronous cancers
  2. Carcinomatosis
  3. Prior surgery, chemotherapy, radiation therapy for the primary tumor or distant metastases

Trial design

200 participants in 2 patient groups

Primary tumour resection group.
Description:
Surgical resection of the primary tumour followed by chemotherapy +/- targeted therapy regime.
Treatment:
Procedure: surgery of the primary tumour
Drug: chemotherapy
Chemotherapy group.
Description:
Chemotherapy +/- targeted therapy alone.
Treatment:
Drug: chemotherapy

Trial contacts and locations

1

Loading...

Central trial contact

Iuliia Alimova, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems